To investigate the association between discordant amyloid-β PET and CSF biomarkers at baseline and the emergence of tau pathology 5 years later.
Introduction
Amyloid-β plaques and neurofibrillary tau tangles are considered the pathological hallmarks of Alzheimer's disease (AD). 1 Amyloid-β pathology can be measured in vivo directly by quantifying the fibrillary depositions using positron emission tomography (PET), or indirectly by detecting the decrease of soluble Aβ42 in cerebrospinal fluid (CSF). Although these two measures are sometimes considered interchangeable, 2-4 10-20% cases show discordant results, especially at earlier stages of AD. [5] [6] [7] Therefore, it has been proposed that decreased Aβ42 in CSF without significant tracer uptake on PET (i.e. amyloid-β CSF+/PET-) marks the pathological beginnings of amyloid-β accumulation. 8, 9 This provides a powerful model to study the dynamic changes in amyloid-β as well as tau pathology during the earliest stages in the disease course of AD. Although CSF tau biomarkers have been available for over two decades, 10 tau PET using radiotracers such as [ 18 F]flortaucipir 11, 12 has only more recently been developed. Tau PET offers the unique opportunity to study the spatial distribution of tau
An open question to date is whether isolated amyloid-β positivity in CSF is followed by significant tau deposition already at this stage, or whether it will be subsequent to more advanced amyloid-β pathology detectable by both modalities (i.e. CSF and PET). As tau has a stronger correlation to neurodegeneration and cognitive function than amyloid-β accumulation, 13, 14 this is of high clinical relevance. Furthermore, a better understanding of the interplay between the AD hallmark pathologies in early disease stages is crucial for the timing of interventions, as emerging treatments will likely be most effective when substantial neurodegeneration has not yet developed. 15 
Methods

Participants
Data for this study was downloaded from the Alzheimer's Disease Neuroimaging Initiative (ADNI) website (http://adni.loni.usc.edu/), which also includes information about ADNI inclusion criteria and the procedure of biomarker acquisition. 16 We selected all ADNI participants, who had at least one [ 18 F]florbetapir amyloid-β PET scan and a CSF Aβ42 analysis available within one year. The diagnosis closest to baseline [ 18 F]florbetapir PET within one year was used as the baseline diagnosis. In total, we included 730 pre-dementia subjects, of Lumbar punctures were performed as previously described. 26 CSF samples were frozen on dry ice after collection and transported to the UPenn Medical Center ADNI Biomarker Core laboratory. Thereafter, 0.5mL aliquots were prepared and stored in polypropylene tubes at -80°C. CSF samples were analyzed for Aβ42, total tau (t-tau) and phosphorylated tau (p-tau) using the AlzBio3 assays (Fujirebio) on the xMAP platform (Luminex). In case samples were reanalyzed, we used the median value of those results. A cutoff of 192 pg/mL was used to determine amyloid-β status based on CSF. 26 28 Thereafter, we created three bilaterally volume-weighted composite regions to cover the full spectrum of tau aggregation: entorhinal cortex, temporal meta-ROI reflecting Braak stage I to IV (including entorhinal, parahippocampal cortex, amygdala, fusiform, inferior and middle temporal cortices), and Braak stage V and VI (including wider neocortical areas). [29] [30] [31] Cut-offs (1.39, 1.34, and 1.28 SUVR, respectively) obtained using a similar PET pipeline were used to determine [ 18 F]flortaucipir positivity. 32 
Statistical analysis
We selected the first available Statistical analysis was performed using R software version 3.5.3. [33] [34] [35] [36] We used linear mixed modelling to investigate longitudinal changes for (i) regional amyloid-β burden assessed by [ 18 F]florbetapir PET, (ii) tau pathology assessed by CSF t-tau, p-tau (measured from baseline) and [ 18 F]flortaucipir PET (measured 5 years after baseline), and (iii) cognitive measures (MMSE, and ADNI memory and executive composite scores). The models included time in years as a continuous variable, amyloid-β CSF/PET group, and an interaction between time*CSF/PET group. All models also included terms for age and sex. The models predicting regional amyloid-β PET and tau pathology based on CSF or PET were additionally adjusted for MMSE to account for clinical disease severity. The models predicting cognitive test results were additionally adjusted for education. We used a random intercept and a random slope for all models. We first selected CSF-/PET-as the reference group and interpreted the main effect of CSF/PET group status (CSF-/PET+ and CSF+/PET-) in the models as difference at baseline, and the CSF/PET group*time interaction term as the change over time. Thereafter, we repeated this analysis with CSF+/PET+ as the reference group. We then performed Kaplan-Meier survival analyses to investigate the association between amyloid-β CSF/PET status and clinical progression by using both overall progression (CN to MCI or dementia, or MCI to dementia) and progression to dementia (CN or MCI to dementia) as events. We additionally used Cox Regression analyses to obtain post hoc Hazard Ratios for each of the amyloid-β CSF/PET profiles.
Finally, we performed two analyses in CSF+/PET-participants only. First, to investigate subthreshold levels of tau pathology in the amyloid-β CSF+/PET-group, we performed linear regression models with amyloid-β pathology measured by [ 18 F]florbetapir PET (globally as well as in early accumulating regions 25 ) at baseline as the outcome, and cross-sectional tau pathology measured by either CSF t-tau or p-tau at baseline, or the three composite regions of 
Data availability
All imaging, demographics, and neuropsychological data used in this article are publicly available and were downloaded from the ADNI website (www.adni.loni.usc.edu). Upon request, we will provide a list of ADNI participant identifications for replication purposes.
Results
Study participants
Of the study participants, 306 (42%) were CSF-/PET-, 80 (11%) CSF+/PET-, 26 (4%) CSF-/PET+ and 318 (44%) CSF+/PET+ (Table 1) . Characteristics were overall similar between CSF-/PET-and the two discordant groups. Participants in the CSF+/PET+ group had a higher proportion of APOE ε4 carriers, were more often diagnosed with MCI, had lower cognitive scores, higher CSF (p)tau levels at baseline and higher [ 18 F]flortaucipir PET uptake five years later.
Accumulation of amyloid-β
First, we assessed regional [ 18 F]florbetapir patterns across groups (Figure 1 , eTable 1 in the Supplement). Although the CSF-/PET+ group had more tracer uptake at baseline than CSF-/PET-, they did not accumulate significantly more amyloid-β over time on PET. Over time, CSF+/PET-group had widespread increase of tracer uptake compared to CSF-/PETirrespective of the reference region. Additionally, CSF+/PET-had slightly more tracer uptake at baseline than CSF-/PET-.
Longitudinal trajectories of tau and cognition
CSF t-tau (p=0.001 and p=0.003), and higher [ 18 F]flortaucipir uptake in entorhinal cortex (p=0.003 and p=0.010) and marginally in the temporal meta-ROI (p=0.062 and p=0.091). 
Accumulation of amyloid-β and tau in CSF+/PET-participants
Discussion
We investigated the association between discordant CSF/PET amyloid-β biomarkers on tau pathology and clinical progression. Our main finding was that although amyloid-β CSF+/PETparticipants showed longitudinal accumulation of amyloid-β based on PET, they had significantly less tau pathology based on both CSF at baseline and [ 18 F]flortaucipir 5 years later compared to participants with CSF+/PET+ amyloid-β status. Similarly, discordant amyloid-β status was associated with better cognitive outcome and a lower risk of clinical progression than CSF+/PET+. We also showed that during follow-up, CSF+/PET-subjects frequently progressed to amyloid-β CSF+/PET+, whereas only one participant reached the threshold of tau-positivity based on [ 18 F]flortaucipir PET. Finally, we showed a correlation between tau measures and global amyloid-β PET tracer uptake, indicating possible subthreshold accumulation of AD pathology in CSF+/PET-subjects. Taken together, our findings suggest that CSF+/PET-amyloid-β status is associated with a distinctly better prognosis than CSF+/PET+, and that a sufficient amyloid-β load detectable by both CSF and PET is required before significant tau deposition emerges.
Using both CSF tau measures and [ 18 F]flortaucipir PET we found that participants with discordant CSF/PET amyloid-β status had less tau pathology than CSF+/PET+ amyloid-β, and comparable tau load as observed in concordant amyloid-β negative participants. It has been proposed that CSF+/PET-status can be caused by CSF Aβ42 being able to detect amyloid-β at an earlier stage due to the decrease of soluble Aβ42 in CSF preceding fibrillary depositions visualized by PET. This is supported by higher rates of CSF+/PET-compared to CSF-/PET+ across several studies. 7, 37, 38 Previous longitudinal PET studies have shown that subjects with CSF+/PET-amyloid-β status show significant accumulation of amyloid-β over time. 8, 9, 39 We replicated this finding in our study, further supporting the notion that CSF+/PET-amyloid-β status identifies the beginnings of amyloid-β accumulation. Although participants with CSF-/PET+ amyloid-β status had higher [ 18 F]florbetapir tracer uptake at baseline, they did not show significant accumulation of amyloid-β over time. Combined with the lack of clinical progression in this group, these observations suggest that isolated amyloid-β PET positivity might be caused by non-specific tracer uptake in the white matter, processing errors or other unknown factors. 6 In CSF+/PET-participants, the lack of substantial tau pathology based on CSF tau measures at baseline and on [ 18 F]flortaucipir PET five years later, accompanied by lack of cognitive decline and clinical progression, suggests these subjects have a distinctly more favorable prognosis than subjects with CSF+/PET+. This is likely caused by the remarkably slow course of AD, which is characterized by gradual accumulation of pathology over time. 40, 41 Accounting for the more benign prognosis of CSF+/PET-subjects is important for the timing of future interventions at the earliest stages of AD pathology.
Current hypothetical biomarker models suggest that accumulation of amyloid-β pathology is followed by detectable cortical tau pathology, subsequently leading to neurodegeneration and cognitive decline. 42, 43 Although it has been proposed that CSF+/PET-is followed by conversion to CSF+/PET+, 8, 44 the exact timing of CSF+/PET-status in regard to that timeline, in particular towards accumulation of tau, is unknown. We found that within five years, one third of the CSF+/PET-participants progressed to CSF+/PET+, whereas at that time only one participant exhibited suprathreshold early to intermediate stage tau pathology based on [ 18 F]flortaucipir PET and none showed widespread neocortical uptake (i.e. Braak stage V/VI regions). This finding has at least two implications. First, as the majority of CSF+/PETparticipants did not progress to CSF+/PET+ within 5 years, this indicates that in the majority of cases the CSF+/PET-amyloid-β status lasts for several years. Second, accumulation of sufficient amyloid-β detectable by both CSF and PET seems to precede significant accumulation of tau pathology. 45 However, we also found a correlation between baseline regional amyloid-β PET and tau pathology in the CSF+/PET-group, suggesting that there already might be interaction present between amyloid-β and tau. This supports previous work, emphasizing the importance of considering subthreshold accumulation of pathology to better understand disease mechanisms of early preclinical stages of AD. [46] [47] [48] Our study has some limitations. Although ADNI is one of the largest cohorts with both available amyloid-β PET and CSF analysis, only a relatively small number of participants with discordant CSF/PET amyloid-β status were available. Second, our main outcome measures of tau pathology based on CSF and PET were assessed at different time-points. Although that reduces the direct comparability of these findings, they also complement each other and allow to measure tau pathology both at baseline and several years later. Additionally, relatively short follow-up periods were available for both CSF tau measures and [ 18 F]flortaucipir PET. Therefore, it is possible, that with longer follow-up periods, subjects with discordant amyloidβ status might show diverging trajectories compared to the CSF-/PET-group. Our interpretation of the study could also be afflicted by the possibility that CSF+/PET-status might reflect a different subtype of AD, although no evidence for that exists. Finally, cut-offs of biomarkers as well as defining amyloid-β PET status based on global SUVR are important considerations when evaluating these results. As suboptimal cut-offs might result in misclassification, 49 we used applied widely used and validated cut-offs for both PET and CSF.
In conclusion, our findings indicate that a sufficient amyloid-β load detectable by both PET and CSF is required before substantial tau deposition emerges. Subjects with CSF+/PETamyloid-β profile are at a significantly earlier clinical and biological disease stage than those with CSF+/PET+, and have a distinctly better prognosis for at least five years. Image was created using the ggseg package in R. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
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